Skip to content
zameds

Flurbiprofen

Sold as Transact, Aryflam, Strepsils intensive, Froben, Froben sr

S1Read from the PI-PIL document and verified
Loading the molecular structure
C15H13FO2244.26 g/mol

2-(3-Fluoro-4-phenylphenyl)propanoic acid

Drag to rotate. Structure from PubChem CID 3394.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
3
Registrations
9
Schedule source
SAHPRA documentation

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Reckitt Benckinser Pharmaceuticals (Pty) LtdCertificate held by Reckitt benckiserTransact, Strepsils intensive8.75mg280268, 350015S1PIPIL
Apotex SA (Pty) LtdCancelledAryflam50 mg, 100 mg320008, 320009Not determinedNone
Abbott Laboratories S.A. (Pty) LtdFroben, Froben sr50, 100, suppositories, syrupK0004, K0005, Q0260, Q0338, V0090Not determinedNone

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Transact

EACH PATCH CONTAINS FLURBIPROFEN 40,0 mg

Not listed28026828/3.1/0268RegisteredNot determinedNone
Aryflam 50 MG

EACH TABLET CONTAINS FLURBIPROFEN 50,0 mg

50 mg32000832/3.1/0008CancelledNot determinedNone
Aryflam100 MG

EACH TABLET CONTAINS FLURBIPROFEN 100,0 mg

100 mg32000932/3.1/0009CancelledNot determinedNone
Strepsils intensive

EACH LOZENGE CONTAINS FLURBIPROFEN 8,75 mg

8.75mgLozenger35001535/16/0015Approved 27 June 2024RegisteredS1PIPIL
Froben 50

EACH TABLET CONTAINS FLURBIPROFEN 50,0 mg

50K0004K/3.1/4RegisteredNot determinedNone
Froben 100

EACH TABLET CONTAINS FLURBIPROFEN 100,0 mg

100K0005K/3.1/5RegisteredNot determinedNone
Froben suppositories

EACH SUPPOSITORY CONTAINS FLURBIPROFEN 100,0 mg

SuppositoriesQ0260Q/3.1/260RegisteredNot determinedNone
Froben syrup

EACH 5 ml CONTAINS FLURBIPROFEN 50,0 mg

SyrupQ0338Q/3.1/338RegisteredNot determinedNone
Froben sr

EACH CAPSULE CONTAINS FLURBIPROFEN 200 mg

Not listedV0090V/3.1/90RegisteredNot determinedNone

Regulatory status

Where S1 sits on the scale

Sold by a pharmacist, no doctor's prescription needed.

Schedule 1 medicines are normally sold by a pharmacist, or by a supervised pharmacist intern or assistant, without a doctor's visit; a veterinarian, or a licensed dispensing doctor, dentist or nurse prescriber, may also supply them. A nurse or other non-doctor prescriber may only prescribe the specific substances the Schedule names for that purpose, and may only dispense them if licensed to do so. A child under 12 may only be sold one of these medicines on a prescription, or on a written order that names the purpose and carries a signature the seller recognises.

Schedule S1, read from the product's PI-PIL leaflet.

The Consolidated Schedules list this ingredient up to S4; the leaflet's S1 applies to this product.

Who may supply: A pharmacist, or a supervised pharmacist intern or assistant; manufacturers and wholesalers supplying people who may lawfully possess it; a veterinarian, who may prescribe, compound or dispense it; a medical practitioner or dentist, who may prescribe it, and may compound or dispense it only if licensed under section 22C(1)(a); a nurse or other registered non-doctor prescriber, who may prescribe only the Scheduled substances the Schedule identifies for that purpose, and dispense them if licensed to do so; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Flurbiprofen

  • S4: Flurbiprofen

    • when intended for ophthalmic use; (S4)
    • except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1)
    • except when intended for application to the skin, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
    • except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)

    Consolidated Schedules 06 July 2026, lines 6390 to 6407

  • S3: Flurbiprofen

    • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
    • when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i). a maximum of 8,75 milligrams per lozenge; (ii). a maximum treatment period of 3 days; and (iii). a maximum pack size of 15 lozenges. (S1)
    • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
    • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
    • when intended for ophthalmic use; (S4)

    Consolidated Schedules 06 July 2026, lines 3609 to 3620

  • S2: Flurbiprofen

    • when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
    • except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii)a maximum pack size of 15 lozenges. (S1)
    • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks; (S0)
    • except when intended for ophthalmic use. (S4)

    Consolidated Schedules 06 July 2026, lines 2014 to 2025

  • S1: Flurbiprofen

    • when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S3)
    • except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0)
    • except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
    • except when intended for ophthalmic use. (S4)

    Consolidated Schedules 06 July 2026, lines 465 to 482

Pharmacological class: Ear, nose and throat preparations (class 16)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Strepsils intensive, Reckitt Benckinser Pharmaceuticals (Pty) Ltd is scheduled S1 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsStrepsils intensive, Reckitt Benckinser Pharmaceuticals (Pty) LtdPatient information leaflet (PIL)For patients and carersStrepsils intensive, Reckitt Benckinser Pharmaceuticals (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles